EP3445341A1 - Utilisation d'homoériodictyol (hed) pour réduire l'effet stimulant la sécrétion d'acide gastrique du n-acétyl-4-aminophénol (paracétamol) - Google Patents

Utilisation d'homoériodictyol (hed) pour réduire l'effet stimulant la sécrétion d'acide gastrique du n-acétyl-4-aminophénol (paracétamol)

Info

Publication number
EP3445341A1
EP3445341A1 EP17717457.0A EP17717457A EP3445341A1 EP 3445341 A1 EP3445341 A1 EP 3445341A1 EP 17717457 A EP17717457 A EP 17717457A EP 3445341 A1 EP3445341 A1 EP 3445341A1
Authority
EP
European Patent Office
Prior art keywords
hed
salts
paracetamol
mixture
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17717457.0A
Other languages
German (de)
English (en)
Inventor
Joachim Hans
Jakob Peter Ley
Susanne Paetz
Silke Middendorf
Kathrin LISZT
Veronika Somoza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symrise AG
Original Assignee
Symrise AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symrise AG filed Critical Symrise AG
Publication of EP3445341A1 publication Critical patent/EP3445341A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • HED Homoeriodictyol
  • the present invention relates, on the one hand, to the non-therapeutic use of homoeriodictyol (HED) for reducing the gastric acid secretion-stimulating effect of N-acetyl-4-aminophenol (paracetamol) and, on the other hand, HED or a salt thereof or a mixture of HED and one or more Salts thereof or a mixture of several salts thereof for use in a therapeutic method for reducing the gastric acid secretion stimulating effect of paracetamol.
  • HED homoeriodictyol
  • paracetamol N-acetyl-4-aminophenol
  • Paracetamol (/ V-acetyl-4-aminophenol; / V-acetyl-p-aminophenol; 4-acetaminophenol; acetaminophen (USAN); APAP; 4'-hydroxyacetanilide;p-hydroxyacetanilide; IUPAC: / V- (4-hydroxyphenyl) Acetamid (Latin: paracetamolum, abbreviation: PCM) is an analgesic and antipyretic drug from the group of nonopioid analgesics and is widely used. Paracetamol, however, has a characteristic, slightly bitter taste that can be perceived as unpleasant. In addition, paracetamol can trigger reflux syndrome by stimulating gastric acid secretion.
  • gastric acid secretion is generally an important mechanism for the initiation of digestion of food, especially protein-rich food dar. It may be quite positive for the digestive system to stimulate the secretion in the short term moderate addition. However, if gastric acid is secreted excessively and thus the pH in the stomach is lowered too much, this usually leads, for example, to discomfort or acid regurgitation. If this condition lasts longer or chronic gastric acid secretion is greatly stimulated, then inflammatory conditions of the gastric mucosa and the esophagus can be induced, which in turn can cause ulceration and in the worst case also malignant tissue changes to gastric cancer and esophageal cancer in turn.
  • the object of the present invention was therefore to specify substances, preferably natural substances, which are suitable for reducing the gastric acid secretion-stimulating effect of paracetamol.
  • substances should be specified which can reduce or even completely prevent acid secretion.
  • two major groups of drugs have been used to reduce or counteract gastric acid secretion, one being (neutralizing) basic substances, such as sodium bicarbonate, calcium carbonate, basic aluminum or magnesium hydroxides, which increase pH, and the other Substances which reduce gastric acid secretion by direct blocking of acetylcholine receptors (M3 type) or more often H2-histamine derivatives, found on the secretory cells (parietal cells), for example pirenzepine, cimetidine, ranitidine or famotidine.
  • M3 type acetylcholine receptors
  • H2-histamine derivatives found on the secretory cells
  • Another way to reduce gastric acid secretion is by direct modulation of the ATP-driven proton pump of parietal cells (see, e.g., opremazole).
  • homoeriodictyol (HED; 3'-methoxy-4 ', 5,7-trihydroxyflavanone) is not only capable of reducing the bitter taste of paracetamol, but also gastric acid secretion -stimulatory effect of paracetamol to reduce, indeed completely prevent.
  • the present invention therefore relates to the non-therapeutic use of homoeriodictyol (HED) or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof for reducing the gastric acid secretion stimulating effect of paracetamol.
  • the present invention also relates to HED or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof for use in a therapeutic method for reducing the gastric acid secretion-stimulating effect of paracetamol.
  • Non-therapeutic uses are preferably those in which the reduction of gastric acid secretion stimulation of paracetamol caused by homoeriodictyol (HED) or a salt thereof, or a mixture of HED and one or more salts thereof or a mixture of several salts thereof Malaise or acid regurgitation, which can be triggered by the sole administration of paracetamol, to prevent or reduce.
  • This type of non-therapeutic use is when individuals have a mixture of HED and / or one or more salts thereof and paracetamol or a preparation containing HED and / or one or more salts thereof and paracetamol only occasionally, i. only a few times a year in low dose, as an analgesic or antipyretic drug use.
  • HED homoeriodictyol
  • HED Homoeriodictyol
  • reduction of gastric acid secretion stimulation of paracetamol serves to prevent inflammatory conditions of the gastric mucosa and the esophagus and thereby caused ulcers or malignant tissue changes to gastric cancer and esophageal cancer, which can be triggered by the sole administration of acetaminophen, or the To reduce severity.
  • This type of therapeutic use is when individuals often a mixture of HED and / or one or more salts thereof and paracetamol or a preparation containing HED and / or one or more salts thereof and paracetamol, ie over a period of many days per Year in high dose, as an analgesic or antipyretic drug use.
  • An example of such a case is chronic pain patients, who often rely on the administration of an analgesic such as paracetamol for pain management.
  • Regular use of paracetamol alone may lead to the above-described pathological changes in the gastric mucosa and esophagus. However, these can be prevented by the additional intake of HED or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof to paracetamol or their training and symptoms are reduced.
  • HED has a bitter masking effect.
  • WO 20141 1 1436 A1 describes that, for example, HED is able to reduce the gastric acid secretion-stimulating effect of various substances, in particular of caffeine or theobromine.
  • WO 20141 1 1436 A1 has shown that administration of HED alone, without the addition of further gastric acid secretion-stimulating substances, does not lead to a significant effect on proton secretion in HGT-1 cells. It is assumed in the present case that this action takes place in the presence of gastric acid secretion-stimulating substances via the modulation of bitter receptors.
  • caffeine has several bitter receptors, e.g. TAS2R43, can activate. From own investigations it is well-known that HED acts as an antagonist on this same receptor type.
  • HED is particularly well suited to reduce the gastric acid secretion-stimulating effect of paracetamol.
  • HED is also described as an agonist at the receptor type TAS2R39 (WSU Roland et al., J Agric. Food Chem., 2013, 61, 10454-10466).
  • TAS2R39 is the only one for Paracetamol known activatable bitter receptor. According to previous findings, it was therefore not predictable, but rather particularly surprising that the combination of a pure TAS2R39 agonist (paracetamol) and a - also - TAS2R39 activating (but other bitter receptor inhibiting) compound (HED) as a result Effect as described herein.
  • HED is not only able to reduce the gastric acid secretion-stimulating effect of paracetamol, but even completely suppress it.
  • HED is even capable of causing a significant reduction in constitutive acid secretion (see, in this regard, the experimental results given in the Examples section).
  • TAS2R39 antagonists bind to the same receptor as TAS2R39 agonists, thereby reducing or eliminating receptor activation of the agonists, as they are unable to activate the receptor.
  • the result of the said study was that antagonists are structurally characterized by having no carbon-carbon double bond between atoms 2 and 3 of the flavanone subclass. This leads to a tetrahedral (angled) conformation at position 2 for antagonists, whereas most agonists have a carbon-carbon double bond and therefore have a planar structure and can penetrate deeper into the binding pocket of the TAS2R39 receptor.
  • the tested flavanones were effective as antagonists only if they had a methoxy group at atom 6.
  • HED is structurally a "hybrid molecule" in terms of its agonistic and antagonistic effects at the TAS2R39 receptor, which has no carbon-carbon double bond between atoms 2 and 3, ie, it has an angled It probably can not penetrate deep into the binding pocket of the receptor just like the antagonists described, but it does not have a methoxy group at position 6 and has three hydroxyl groups to form hydrogen bonds, which in turn suggests agonist activity at the TAS2R39 receptor
  • the presence of three hydroxyl groups in the structure of HED could potentially result in HED binding competitively to paracetamol at the TAS2R39 receptor, with greater binding affinity than paracetamol to the TAS2R39 receptor through its greater ability to form hydrogen bonds his ge
  • angled structures probably did not like the planar agonists penetrate deep into the binding pocket of the receptor and
  • HED in the literature as a TAS2R39 agonist and its structure containing mainly agonist-acting elements, the strong reduction of the gastric acid secretion-stimulating effect of paracetamol by HED is an unexpected effect, especially in the extent described herein.
  • the proton secretion induced by the administration of 3 mM paracetamol can not only be reduced or abolished in HGT-1 cells; in this case, surprisingly, less acid is produced by the HGT-1 cells secreted as in the control experiment, which is performed without the addition of active substances to the cells (overcompensation).
  • the use further comprises masking the bitter taste of paracetamol.
  • a bitter taste of an orally administered drug may severely adversely affect the acceptance of the drug containing that drug and the compliance of individuals. Therefore, it is important to provide substances that mask the bitter taste of a substance in a mixture or preparation containing the bittering agent.
  • bitter taste impression regularly means an improvement in taste, in particular with regard to bitter taste impressions.
  • the said flavor improvement can be achieved by various strategies.
  • unpleasant, bitter taste sensations have been masked by the addition of pleasurable flavors. This is a mere masking of the bitter taste impression.
  • a second approach to reduce or completely suppress a bitter taste sensation of a bittering agent is to prevent contact of the bittering agent with the bittering receptors, for example by encapsulation, molecular entrapment or complexation.
  • a third strategy of masking is the use of so-called bitter-blockers (antagonists).
  • 6-methoxyflavanone can reduce the response of the receptor to various bitter substances (agonists) (Roland et al., 6-Methoxyflavanones as Bitter Taste Receptor Blockers for hTAS2R39, PLoS ONE 2014, 9 (4 ), e94451).
  • 6-methoxyflavanone according to Roland et al. (2015) clearly have a structure associated with TAS2R39 receptor antagonists, i. it has no carbon-carbon double bond between atoms 2 and 3 (bent structure), it has a methoxy group at position 6 and no hydrogen bond donor groups.
  • HED and paracetamol are contained together in a preparation in the context of a use according to the invention. That is, preferably, a use (as described above) in a preparation containing HED and / or one or more salts thereof and paracetamol, wherein the amount of HED and / or salt (s) thereof is sufficient to the gastric acid secretion-stimulating effect of reducing acetaminophen and, preferably, moreover sufficient to mask the bitter taste of paracetamol.
  • Suitable preparations are, for example, those which are formed in a form which is selected from the group consisting of: tablets (uncoated and coated tablets, single or multilayer tablets), capsules, dragees, granules, pellets, solid mixtures, dispersions in liquid phases , Emulsions, powders, solutions, juices, pastes or other swallowable or chewable preparations, preferably those selected from the group consisting of tablets, capsules, juices, chewing gums or fruit gums.
  • Further customary active substances, basic substances, auxiliaries and additives may be present in the preparation in amounts of from 0.9 to 99.999999% by weight, preferably from 10 to 80% by weight, based on the total weight of the preparation.
  • the preparations may contain water in an amount of up to 99.999999% by weight, preferably 5 to 80% by weight, based on the total weight of the preparation.
  • the preparation preferably additionally comprises one or more constituents selected from the group consisting of eriodictyol, phloretin, hesperetin, 2,4-dihydrobenzoic acid / V-vanillylamide, 5,7-dihydroxy-4- (4-hydroxyphenyl) chroman- 2-one, 5,7-dihydroxy-4- (4-hydroxy-3-methoxy-phenyl) -chroman-2-one, 5,7-dihydroxy-4- (4-pyridyl) -chroman-2-one, 7,3-dihydroxy-4'-methoxyflavan, lariciresinol and matairesinol, and their respective (if applicable) single or mixed stereoisomers (diastereomers or enantiomers).
  • the HED or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof and paracetamol can be administered to an individual either simultaneously in a common preparation or they can be staggered one after the other in different ways within the scope of the present invention Preparations are administered. That is, the HED and / or one or more salts thereof may be administered to an individual before, during or after the administration of paracetamol. Preferably, the HED and / or one or more salts thereof and the paracetamol are administered to an individual simultaneously in the same preparation.
  • the HED and / or one or more salts thereof and the paracetamol in admixed form present (eg in a single-layer tablet) or they may be in separate layers (eg in a bilayer or multilayer tablet).
  • the release of the HED and / or one or more salts thereof and of the paracetamol can in this case take place in two-layered or multi-layered tablets (or other formulation forms) after oral administration, again simultaneously or at different times.
  • the release of HED and / or one or more salts thereof occurs prior to the release of the paracetamol or simultaneously with the release of the paracetamol.
  • the gastric acid secretion stimulating effect of paracetamol by HED and / or the salt (s) thereof is not only greatly reduced, but there is a significant reduction in the constitutive acid secretion of HGT-1 cells (overcompensation ), ie in the cell assay described in the Examples section (see Table 1), the acid secretion level of the HGT-1 cells after the administration of paracetamol and HED and / or one or more salts thereof is lower than in the case of an untreated control which was not exposed to either paracetamol or HED.
  • the gastric acid secretion stimulating effect of paracetamol by HED and / or salt (s) thereof is reduced by at least 150%, especially when compared to an identical preparation without HED and / or salt (s) thereof preferably by at least 200%, most preferably by up to 300%.
  • the concentration of HED and / or salt (s) thereof in the preparation is in the range of 0.000001 to 30 mM, preferably in the range of 0.00001 to 3 mM, more preferably in the range of 0.0001 to 1 mM, more preferably in the range of 0.001 to 0.4 mM.
  • the concentration of paracetamol in the preparation is in the range of 0.001 to 1000 mM, preferably in the range of 0.01 to 800 mM, more preferably in the range of 0.1 to 750 mM, most preferably in Range from 1 to 600 mM.
  • the ratio of the total concentration of HED and / or salt (s) thereof to the total concentration of paracetamol within the scope of a use according to the invention, in particular in a preparation (as described above) is in the range from 1: 100,000 to 1: 1 , preferably in the range of 1: 10,000 to 1: 2, more preferably in the range of 1: 5000 to 1:10, particularly preferably in the range of 1: 2000 to 1:20.
  • HED or salts thereof occur in a variety of plants.
  • the main source is the family of Hydrophyllaceae Eriodictyon ssp., Better known as Herba Santa or Yerba Santa. Methods for providing or isolating HED and salts thereof, but also other ways to obtain HED and its salts, are now well known to those skilled in the art.
  • salts of HED are used in the context of a use according to the invention, it is considered that the or one, several or all salts of HED are preferably selected from the group consisting of sodium, potassium, calcium and ammonium -Salt. In the context of the present application, the following methods are also described:
  • a method of reducing the gastric acid secretion-stimulating effect of paracetamol in an orally consumable pharmaceutical preparation comprising the step of adding HED or a salt thereof or a mixture of HED and one or more salts thereof or a mixture of several salts thereof to a pharmaceutical
  • a composition comprising paracetamol in an amount sufficient to reduce the gastric acid secretion stimulating effect of paracetamol and, more preferably, sufficient to mask the bitter taste of paracetamol.
  • a method for reducing gastric acid secretion in an individual receiving paracetamol comprising the step of administering to the individual before or concurrently with paracetamol HED or a salt thereof or a mixture of HED and one or more salts (e ) thereof or a mixture thereof of a plurality of salts, in an amount sufficient to reduce the gastric acid secretion stimulating effect of paracetamol and, more preferably, sufficient to mask the bitter taste of paracetamol.
  • human parietal cells human gastric tumor cell line, HGT-1
  • HGT-1 human gastric tumor cell line
  • HGT-1 human parietal cells
  • the dye 1 5-carboxy-seminaphtharhodafluoro-acetoxymethyl ester (SNARF-1 -AM) is used.
  • the cells in the 96-well plates are washed once with Krebs-Hepes buffer (KRHP) and incubated with the dye in the concentration of 3 ⁇ dissolved in KRHP for 30 min at 37 ° C and 5% C0 2 .
  • KRHP Krebs-Hepes buffer
  • the cells are washed twice with KRHP and with gastric acid secretion-stimulating substances, for example 3 mM caffeine, 0.3 mM theobromine or 3 mM paracetamol alone or in combination with substances to reduce the gastric acid-stimulating effect of the preceding substances, for example homoeriodictyol ( HED), in different concentrations in phenol red-free DMEM in the volume of 100 ⁇ _ applied; as a further control experiment, the gastric acid secretion-stimulating substances mentioned above are tested alone.
  • Homoeriodictyol is dissolved in double distilled water. The final concentration of solvent supplied to the cells is at most 1%.
  • the fluorescent dye is excited at the wavelength of 488 nm and the emission is measured at 580 nm and 640 nm.
  • the ratio of the fluorescence values from 580 nm to 640 nm is plotted in comparison to the calibration curve, from which the pH value can be determined.
  • the cells are treated with a potassium buffer of pH 7.2-8.2 and 2 ⁇ nigericin. Nigericin equilibrates the intracellular and extracellular pH, so that the intracellular pH can be defined.
  • the intracellular H + concentration is determined from the intracellular pH.
  • IPX intracellular proton index
  • the number of indicated replicates refers to technical replicas (tr) or to the number of total replicates (n), which is the number of technical replicates multiplied by the number of biological replicates.
  • Table 1 the measured percentage increase (positive values) and percentage reduction (negative values) of proton secretion in HGT-1 cells after 10 minutes of stimulation by 3 mM caffeine, 0.3 mM theobromine or 3 mM paracetamol alone or in combination with homoeriodictyol (HED) in different concentrations.
  • HED homoeriodictyol
  • HED significantly reduces the increase in proton secretion after administration of acetaminophen.
  • simultaneous incubation of the cells with 0.3 mM paracetamol and only 0.003 mM HED the proton secretion increases by only 1 1%.
  • Concurrent incubation of the cells with 3 mM paracetamol and 0.03 mM HED increases proton secretion by only 7%.
  • Concurrent incubation of the cells with 3 mM paracetamol and 0.3 mM HED significantly reduces proton secretion by 46%.
  • HED-1 homoeriodictyol, purity 95% (Interquim, Spain)
  • HED-2 homoeriodictyol sodium salt
  • Variant 1 10 g homoeriodictyol (95%) are placed in the flask and 44 g NaOH solution 3% ig added. The first dark brown solution is quickly mushy, then diluted with water until homogeneous suspension and stirred for 1 hour and then freeze-dried or spray-dried. Yield: 10.44 g; HPLC: 94.2% HED-Na versus standard HED-3: homoeriodictyol sodium salt variant 2:
  • HED-4 Homoeriodictyol sodium salt, of course, was prepared according to WO 2004/041804.
  • HED-5 60.8% by weight of water are initially charged and 6.1% by weight of gum arabic and 24.3% by weight of maltodextrin (from corn starch) are dissolved. 8.8% by weight of the homoenodictylol sodium salt (HED-2, HED-3 or HED-4) are added and mixed with an Ultraturrax or another homogenizer. The emulsified suspension is then spray-dried in a spray tower (inlet temperature 185-195 ° C, outlet temperature 70-75 ° C) and obtained with about 18-22% Homoeriodictyol laden spray product.
  • a spray tower inlet temperature 185-195 ° C, outlet temperature 70-75 ° C
  • HED-6 2.5% by weight of homoeriodictyol (HED-1) are dissolved in 1,2-propylene glycol
  • HED-7 1% by weight of homoeriodictyol sodium salt (HED-2, HED-3 or HED-4) are dissolved in ethanol
  • HED-5 powdered HED sodium salt on maltodextrin
  • Excipients Purified water, sucrose, sodium citrate, tragacanth,
  • Citric acid methyl 4-hydroxybenzoate (E218), propyl 4-hydroxybenzoate (E216).
  • Excipients citric acid, sodium citrate, sucrose 3.7g, saccharin sodium salt, sodium cyclamate, corn starch, high d. Silica, ascorbic acid, maltodextrin, butylhydroxyanisole, modified starch, curcumin, orange flavor.
  • 1 effervescent tablet contains:
  • Excipients ascorbic acid, citric acid, lactose 1 H20, macrogol 6000, methylcellulose, sodium cyclamate, sodium bicarbonate, sodium sulphate, povidone K25, saccharin sodium salt, simethicone, sorbic acid, lemon flavor
  • HED-3 Homoeriodictyol sodium salt variant 2
  • Excipients sodium metabisulphite (E223), propylene glycol, saccharin sodium salt, sorbitol sol. 70% (non-crystalline) (E420), eng. Water, aroma type cherry
  • Tablets 1 tablet contains:
  • Excipients glycerol, sodium metabisulphite, citric acid, sodium hydroxide, acesulfame potassium salt, red fruit flavoring, macrogol, saccharin sodium salt, purified water
  • 1 tablet contains:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne principalement l'utilisation d'homoériodictyol (HED) ou d'un sel de ce dernier ou d'un mélange d'HED et d'un ou de plusieurs sels d'HED ou un mélange de plusieurs sels d'HED pour réduire l'effet stimulant la sécrétion d'acide gastrique du N-acétyl-4-aminophénol (paracétamol).
EP17717457.0A 2016-04-20 2017-04-19 Utilisation d'homoériodictyol (hed) pour réduire l'effet stimulant la sécrétion d'acide gastrique du n-acétyl-4-aminophénol (paracétamol) Withdrawn EP3445341A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16166222.6A EP3235492B1 (fr) 2016-04-20 2016-04-20 Utilisation d'homoeriodictyol (hed) destine a reduire l'effet de stimulation de la secretion de l'acide gastrique de n-acetyl-4-aminophenol (paracetamol)
PCT/EP2017/059315 WO2017182538A1 (fr) 2016-04-20 2017-04-19 Utilisation d'homoériodictyol (hed) pour réduire l'effet stimulant la sécrétion d'acide gastrique du n-acétyl-4-aminophénol (paracétamol)

Publications (1)

Publication Number Publication Date
EP3445341A1 true EP3445341A1 (fr) 2019-02-27

Family

ID=55910743

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16166222.6A Active EP3235492B1 (fr) 2016-04-20 2016-04-20 Utilisation d'homoeriodictyol (hed) destine a reduire l'effet de stimulation de la secretion de l'acide gastrique de n-acetyl-4-aminophenol (paracetamol)
EP17717457.0A Withdrawn EP3445341A1 (fr) 2016-04-20 2017-04-19 Utilisation d'homoériodictyol (hed) pour réduire l'effet stimulant la sécrétion d'acide gastrique du n-acétyl-4-aminophénol (paracétamol)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP16166222.6A Active EP3235492B1 (fr) 2016-04-20 2016-04-20 Utilisation d'homoeriodictyol (hed) destine a reduire l'effet de stimulation de la secretion de l'acide gastrique de n-acetyl-4-aminophenol (paracetamol)

Country Status (3)

Country Link
US (1) US11013714B2 (fr)
EP (2) EP3235492B1 (fr)
WO (1) WO2017182538A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10122898A1 (de) * 2001-05-11 2002-11-14 Haarmann & Reimer Gmbh Verwendung von Hydroxyflavanonen zur Maskierung des bitteren Geschmacks
DE10252532A1 (de) 2002-11-08 2004-05-27 Symrise Gmbh & Co. Kg Technisches Verfahren zur Isolierung von Flavanonen
EP2946208A1 (fr) * 2013-01-17 2015-11-25 Universität Wien Procédé d'identification de composés au goût amer et de composés modulant le goût amer
EP2756765B1 (fr) 2013-01-17 2019-03-27 Symrise AG Compositions pharmaceutiques

Also Published As

Publication number Publication date
WO2017182538A1 (fr) 2017-10-26
US20190091199A1 (en) 2019-03-28
EP3235492B1 (fr) 2019-06-12
US11013714B2 (en) 2021-05-25
EP3235492A1 (fr) 2017-10-25

Similar Documents

Publication Publication Date Title
WO2001015682A1 (fr) Sels pharmaceutiques de tramadol
KR101490721B1 (ko) 감칠맛을 가진 디페리프론용 액상 제제
DE3786893T2 (de) Piperidinderivat zur Schmerzbehandlung.
EP2057994A1 (fr) Préparation d'extrait de cactus à figues
DE69913116T2 (de) Orale flüssige lösung enthaltend das antidepressivum mirtazapine
EP3278793A1 (fr) Composition pour le traitement de la veisalgie
WO2008011915A1 (fr) Masquage de goût de compositions contenant du sel
DE3338978A1 (de) Verapamil und gallopamil und ihre physiologisch vertraeglichen salze zur resorptiven anwendung auf den schleimhaeuten des mundes, des nasen-rachen-raums und des rektums
DE2726392A1 (de) Mittel zur bekaempfung der venoesen thrombose
EP2981275A1 (fr) Comprimé à sucer pour le traitement des maux de gorge, de l'enrouement et des toux sèches associées, ainsi que des maladies de la cavité buccale et pharyngale
DE69912978T2 (de) Oral anzuwendendes sertralinhaltiges konzentrat
DE10392164T5 (de) Oral verabreichbare pharmazeutische Formulierung
EP3235492B1 (fr) Utilisation d'homoeriodictyol (hed) destine a reduire l'effet de stimulation de la secretion de l'acide gastrique de n-acetyl-4-aminophenol (paracetamol)
DE3445183A1 (de) Proglumide enthaltende arzneimittel mit analgetischer wirkung
DE3034975C2 (de) Arzneimittelkombination zur Behandlung infektiöser Atemwegerkrankungen
DE19815411A1 (de) Thermogenese stimulierend wirksame Arzneimittel
DE3141970C2 (fr)
DE10163667A1 (de) Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
AT414095B (de) Sialagogum auf basis einer lebensmittelsäure
EP1150660B1 (fr) Formulation effervescente pharmaceutique contenant du metamizol
EP2818167A1 (fr) Composition pharmaceutique antivirale active
DE60311134T2 (de) Oromukosale formulierung und herstellungsverfahren dafür
DE69736955T2 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen
DE2134672A1 (de) Wasserloesliches acetylsalicylsaeuresalz, dessen herstellung, zubereitung und anwendung
DE102004008375B4 (de) Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603